← Browse by Condition
Medical Condition

takotsubo cardiomyopathy

Total Trials
4
Recruiting Now
4
Trial Phases
Various

ClinicalMetric tracks all active clinical trials for takotsubo cardiomyopathy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — takotsubo cardiomyopathy Clinical Trials

How many clinical trials are currently recruiting for takotsubo cardiomyopathy?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for takotsubo cardiomyopathy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for takotsubo cardiomyopathy?
takotsubo cardiomyopathy research spans multiple clinical trial phases. Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a takotsubo cardiomyopathy clinical trial?
Eligibility criteria for takotsubo cardiomyopathy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
Salamanca University Hospital 1 trial
University of Aberdeen 1 trial
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 trial
University of Edinburgh 1 trial

Recruiting Clinical Trials

NCT06506071
Recruiting

Characterization of Acute Myocardial Damage With Spectral Computed Tomography. (CADAMI-SPECTRAL)

Enrollment
300 pts
Location
Spain
Sponsor
Salamanca University Hospital
View Trial →
NCT04513054
Recruiting

Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy

Enrollment
700 pts
Location
United Kingdom
Sponsor
University of Aberdeen
View Trial →
NCT05793008
Recruiting

Characterization of priMary And sEcondary STress Related takOtsubo

Enrollment
60 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
View Trial →
NCT07491718
Recruiting

Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

Enrollment
100 pts
Location
United Kingdom
Sponsor
University of Edinburgh
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology